Literature DB >> 30676653

NK cell metabolism.

Clair M Gardiner1.   

Abstract

Natural Killer (NK) cells are important antiviral and anticancer effector cells. They have excellent potential for immunotherapy although impaired functions during cancer limit their effectiveness. The discovery that cellular metabolism can impact on and regulate immune functions has led to an explosion of articles in this new area of immunometabolism. Metabolism has recently been shown to impact both murine and human NK cell biology. This review is targeted for newcomers to the field; it will introduce basic concepts in the area of immunometabolism including key aspects of glucose metabolism and mitochondrial function. It will review our current understanding of how metabolism of NK cells is differentially impacted in a variety of important situations. This is a rapidly expanding and exciting area of research that holds great potential for improving NK cell-based immunotherapies. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  NK; Natural Killer; Oxphos; glycolysis; metabolism

Year:  2019        PMID: 30676653     DOI: 10.1002/JLB.MR0718-260R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  22 in total

Review 1.  Lipid Metabolism in Tumor-Associated Natural Killer Cells.

Authors:  Yu Chen; Meihua Sui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes.

Authors:  Xiaofeng Mu; Zheng Xiang; Yan Xu; Jing He; Jianwen Lu; Yuyuan Chen; Xiwei Wang; Chloe Ran Tu; Yanmei Zhang; Wenyue Zhang; Zhinan Yin; Wing-Hang Leung; Yu-Lung Lau; Yinping Liu; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2022-07-11       Impact factor: 22.096

3.  Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.

Authors:  Xiaodong Wang; Jing Qian; Ninghua Yao; Christine Pocha; Koo Jeong Kang; Roberta Angelico; Guodong Zhu
Journal:  Ann Transl Med       Date:  2022-05

Review 4.  Modulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic Inflammation.

Authors:  Madlen Kaldirim; Alexander Lang; Susanne Pfeiler; Pia Fiegenbaum; Malte Kelm; Florian Bönner; Norbert Gerdes
Journal:  Front Cardiovasc Med       Date:  2022-06-29

5.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.

Authors:  Huang Zhu; Robert H Blum; Davide Bernareggi; Eivind Heggernes Ask; Zhengming Wu; Hanna Julie Hoel; Zhipeng Meng; Chengsheng Wu; Kun-Liang Guan; Karl-Johan Malmberg; Dan S Kaufman
Journal:  Cell Stem Cell       Date:  2020-06-11       Impact factor: 24.633

6.  Metabolic changes of Interleukin-12/15/18-stimulated human NK cells.

Authors:  Iñigo Terrén; Ane Orrantia; Alba Mosteiro; Joana Vitallé; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  Sci Rep       Date:  2021-03-19       Impact factor: 4.379

Review 7.  NK Cell Dysfunction and Checkpoint Immunotherapy.

Authors:  Jiacheng Bi; Zhigang Tian
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

8.  Overcoming the UCB HSCs -Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways.

Authors:  Alireza Shokouhifar; Gholamreza Anani Sarab; Mahboubeh Yazdanifar; Mohammad Fereidouni; Masoumeh Nouri; Marzieh Ebrahimi
Journal:  Cancer Cell Int       Date:  2021-06-07       Impact factor: 5.722

9.  Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth.

Authors:  Shuwei Guo; Chao Huang; Fengfeng Han; Bin Chen; Ying Ding; Yuanyuan Zhao; Zhihong Chen; Shaodi Wen; Mei Wang; Bo Shen; Wei Zhu
Journal:  Stem Cells Int       Date:  2021-06-29       Impact factor: 5.443

Review 10.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.